Artal Group’s Metacrine, Inc. Common Stock MTCR Stock Holding History

Artal Group’s Portfolio MTCR Stock Details MTCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-924,898	Closed	-$528K	–	141
2023 Q1	$528K	Hold	924,898	–	–	0.03%	103
2022 Q4	$414K	Hold	924,898	–	–	0.02%	117
2022 Q3	$449K	Hold	924,898	–	–	0.02%	124
2022 Q2	$462K	Hold	924,898	–	–	0.02%	124
2022 Q1	$564K	Hold	924,898	–	–	0.02%	132
2021 Q4	$624K	Hold	924,898	–	–	0.02%	147
2021 Q3	$3.17M	Hold	924,898	–	–	0.07%	126
2021 Q2	$3.52M	Hold	924,898	–	–	0.07%	127
2021 Q1	$5.73M	Hold	924,898	–	–	0.1%	120
2020 Q4	$7.27M	Sell	924,898 -384,615	-29%	-$3.53M	0.16%	98
2020 Q3	$13.4M	Buy	+1,309,513	New	+$13.4M	0.32%	68

Artal Group's MTCR Position: Q2 2023 in Review

Artal Group sold out of Metacrine, Inc. Common Stock (MTCR) in Q2 2023, closing a stake of 924,898 shares — an estimated $528K sold.

Artal Group first reported a position in MTCR in Q3 2020 and held it in 11 quarters. The position peaked at $13.4M in Q3 2020. 0 funds tracked by Wall St. Rank hold MTCR as of Q2 2023.

Artal Group reported no remaining Metacrine, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Artal Group sold 924,898 Metacrine, Inc. Common Stock shares in Q2 2023, an estimated $528K.
Artal Group first reported a position in Metacrine, Inc. Common Stock in Q3 2020 and held it in 11 quarters.
Artal Group's Metacrine, Inc. Common Stock position peaked at $13.4M in Q3 2020.
0 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q2 2023.

Based on Artal Group's 13F filing for Q2 2023, filed 11 Aug 2023.